The SVP & GC of Depomed (NASDAQ: DEPO) is Selling Shares

By Carrie Williams

Yesterday, the SVP & GC of Depomed (NASDAQ: DEPO), Matthew Gosling, sold shares of DEPO for $673.2K.

In addition to Matthew Gosling, one other DEPO executive reported Sell trades in the last month.

The company has a one year high of $27.02 and a one year low of $9.50. Currently, Depomed has an average volume of 1.65M.

Based on 5 analyst ratings, the analyst consensus is Hold with an average price target of $14.5, reflecting a -18.9% downside.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Depomed, Inc. is a pharmaceutical company, which manufactures and distributes pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Newark, CA.